VEGFA and breast carcinoma: Investigators of the randomized phase III GeparQuinto study tested whether SNPs in VEGF pathway genes correlate with complete pathological response after neoadjuvant treatment in 729 patients treated with bevacizumab and chemotherapy and in 725 treated only with chemotherapy for HER-2 negative breast cancer.